Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Inclusion Criteria: 1. Histologically or cytologically confirmed unresectable local advanced/recurrent or metastasis esophageal squamous cell carcinoma; 2. No previous systemic anti-tumor treatment; 3. Subjects must have at least one measurable tumor lesion per RECIST 1.1; 4. Tissue samples should be provided for biomarkers (such as PD-L1) analysis; 5. ECOG: 0-1; 6. Adequate organ and bone marrow function; Exclusion Criteria: 1. Allergic to monoclonal antibodies, any SHR-1210 components, paclitaxel, cisplatin and other platinum drugs; 2. Prior therapy as follow: 1. Anti-PD-1 or anti-PD-L1; 2. Any experimental drugs within 4 weeks of the first dose of study medication; 3. Received major operations or serious injuries within 4 weeks of the first dose of study medication; 4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication; 3. Not recovered to ≤CTCAE 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment; 4. Subjects with any active autoimmune disease or history of autoimmune disease; 5. Pregnancy or breast feeding;